Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 5, 2008Breast Cancer ResearchOpen Access

Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity

View Full Paper
Ask AI
Bookmark
Share

Authors

SHSacha J. HowellUniversity of ManchesterÉAÉlizabeth AndersonSierra Leone Urban Research CentreTHTom Hunter

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Howell et al. (2008) studied this question.

synapsesocial.com/papers/6a8c80f17b1ef46d2ffdf59ahttps://doi.org/10.1186/bcr2129
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Isolation and <i>In vitro</i> Propagation of Tumorigenic Breast Cancer Cells with Stem/Progenitor Cell Properties2005 · 1,734 citations
  2. 2PRL Modulates Cell Cycle Regulators in Mammary Tumor Epithelial Cells2002 · 88 citations
  3. 3Evidence for a second receptor binding site on human prolactin.1994 · 71 citations
  4. 4Prolactin inhibits apoptosis of ovarian carcinoma cells induced by serum starvation or cisplatin treatment2005 · 35 citations
  5. 5Src Mediates Prolactin-Dependent Proliferation of T47D and MCF7 Cells via the Activation of Focal Adhesion Kinase/Erk1/2 and Phosphatidylinositol 3-Kinase Pathways2003 · 133 citations